

A phase III, single-blind trial to assess efficacy and tolerability of genital mucosa after use of product INC056

Submission date 18/07/2008	Recruitment status No longer recruiting	☒ Prospectively registered
Registration date 01/08/2008	Overall study status Completed	☐ Protocol
Last Edited 05/08/2008	Condition category Urological and Genital Diseases	☐ Statistical analysis plan
		☐ Results
		☐ Individual participant data
		☐ Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr André Luiz Vergnanini

Contact details

Rua Vicente Porto, 660.
Barão Geraldo
Campinas
Brazil
13085-080

Additional identifiers

Protocol serial number

INC056-01

Study information

Scientific Title

A phase III, single-blind, single-centre trial to assess efficacy and tolerability of genital mucosa after use of product INC056 in post-menopausal women

Study objectives

This study is to confirm the safety, tolerability and efficacy of INC056 in post-menopausal female volunteers.

Hypothesis:

This treatment is expected to lower the vaginal pH in post-menopausal women and thus, to relieve local irritability and dryness of vagina.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethical approval received from the Ethics Committee of Irmandade de Misericórdia de Campinas - Hospital Irmãos Penteado (Brazil) on the 10th December 2007

Primary study design

Interventional

Study design

A phase III, single-centre, non-randomised, non-controlled, single-blind study

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Local irritability and dryness of vagina

Interventions

Pre-trial visit:

Prior to interventions, written informed consent will be gained. Screening assessment, vaginal pH testing, gynaecological exam and interview will be performed. The dose is one disposable applicator full of INC056 product (approximately 4 grams), applied intravaginally at bedtime.

Volunteers will be instructed to administrate the product as following:

1. Once every 3 days during 30 days
2. A 7 days washout period
3. Once daily for next 14 days

Visits will be performed on days 15, 30, 37 and 53.

Intervention Type

Drug

Phase

Phase III

Drug/device/biological/vaccine name(s)

INC056

Primary outcome(s)

Evaluate vaginal acidification after product use (lowering of vaginal pH) at all visits (baseline and days 14, 30, 37 and 52).

Key secondary outcome(s)

The following will be assessed at all visits (baseline and days 14, 30, 37 and 52):

1. Assessment of all adverse events reported
2. Assessment of vaginal dryness and/or sexual discomfort
3. Occurrence of recurrent vaginal infections in volunteers
4. Investigator's Global Assessment
5. Volunteer's Global Assessment
6. Assessment measured by acceptability questionnaire
7. Interruption of use due allergic reactions or irritability

Completion date

01/02/2009

Eligibility

Key inclusion criteria

1. Healthy female volunteers aged between 40 and 65 years
2. Post-menopausal women
3. Vaginal pH of 5.0 or higher
4. Written informed consent

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

Female

Key exclusion criteria

1. Pregnancy or lactation
2. Skin disease at site of administration
3. Diabetes mellitus
4. Immunological insufficiency
5. Use of systemic corticoid, antibiotics or steroids
6. Use of immunosuppressive drugs
7. Skin diseases: vitiligo, psoriasis, lupus, atopic dermatitis
8. Antifungal therapy within the last month at screening
9. History of infection at the site of drug administration
10. History of allergies to components of product
11. Other diseases or medications that could interfere with the research result or endanger the volunteer

Date of first enrolment

01/10/2008

Date of final enrolment

01/02/2009

Locations

Countries of recruitment

Brazil

Study participating centre

Rua Vicente Porto, 660.

Campinas

Brazil

13085-080

Sponsor information

Organisation

Incrementtha PD&I (Brazil)

Funder(s)

Funder type

Industry

Funder Name

Incrementtha PD&I (Brazil)

Results and Publications

Individual participant data (IPD) sharing plan**IPD sharing plan summary**

Not provided at time of registration